Capital Fund Management S.A. Allogene Therapeutics, Inc. Transaction History

Capital Fund Management S.A.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$4.92 - $8.21 $476,875 - $795,762	-96,926 Reduced 32.77%	198,855 $982,000
Q4 2022 Feb 13, 2023	BUY	$5.62 - $11.11 $1.3 Million - $2.57 Million	230,979 Added 356.44%	295,781 $1.86 Million
Q3 2022 Nov 14, 2022	SELL	$10.32 - $17.28 $456,546 - $764,449	-44,239 Reduced 40.57%	64,802 $700 Million
Q2 2022 Aug 12, 2022	BUY	$6.78 - $12.28 $31,784 - $57,568	4,688 Added 4.49%	109,041 $1.24 Million
Q1 2022 May 12, 2022	BUY	$7.65 - $15.29 $798,300 - $1.6 Million	104,353 New	104,353 $950,000
Q2 2020 Aug 13, 2020	SELL	$18.39 - $54.04 $190,189 - $558,881	-10,342 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$18.22 - $28.25 $188,431 - $292,161	10,342 New	10,342 $201,000

162

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $326M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

Stay updated on Capital Fund Management S.A. with notifications on news.